Compugen Announces Interim Analysis Timeline for MAIA-Ovarian Trial of COM701 as Maintenance Therapy in Platinum-Sensitive Ovarian Cancer
I'm PortAI, I can summarize articles.
Compugen Ltd. has announced an interim analysis timeline for its MAIA-ovarian trial, evaluating COM701 as a maintenance therapy in platinum-sensitive ovarian cancer. The analysis will occur after data from about 60 participants is collected, with results expected by the end of 2026. Clinical sites have been activated in the U.S., Israel, and France to support enrollment. Additionally, a pooled analysis of COM701 from three Phase 1 trials will be presented at ESMO 2025, with the abstract available on the company’s website and the poster set for release on October 18, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments